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The joint modelling of brain imaging information and genetic
data is a promising research avenue to highlight the functional
role of genes in determining the pathophysiological mechanisms
of Alzheimer’s disease (AD). However, since genome-wide asso-
ciation (GWA) studies are essentially limited to the exploration
of statistical correlations between genetic variants and pheno-
type, the validation and interpretation of the findings is usually
non trivial and prone to false positives. To address this issue,
in this work we investigate the genetic functional mechanisms
underlying brain atrophy in AD by studying the involvement of
candidate variants in known genetic regulatory functions. This
approach, here termed functional prioritization, aims at testing the
sets of gene-variants identified by high-dimensional multivariate
statistical modelling with respect to known biological processes,
in order to introduce a biology-driven validation scheme. When
applied to the ADNI cohort, the functional prioritization allowed
identifying a link between TRIB3 (tribbles pseudokinase 3) and
the stereotypical pattern of grey matter loss in AD, which was
confirmed in an independent validation sample, and that provides
novel evidence about the relation between this gene and known
mechanisms of neurodegeneration.
imaging-genetics j Alzheimer's disease j brain atrophy j TRIB3 j neu-
roimaging
Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder and its aetiology still remains largely concealed. In the
anticipation of increasing prevalence of AD and other dementias,
there is an urgent need for improving the understanding of the
disease processes that underlie neurodegeneration. Whilst the
knowledge about the genetic and environmental risks underpin-
ning AD is steadily advancing, our understanding of how these
factors interact to lead to the complex pathophysiology that
results in dementia is less understood.
Advances in imaging technologies have led to non- or
minimally-invasive imaging biomarkers that capture various as-
pects of the disease process including amyloid deposition [1], tau
pathology [2], functional decline [3] and neuronal loss [4]. Com-
bining such imaging information with genetic measurements – so
called imaging-genetics – provides the means for investigating the
effect of genetic variation on underlying biological mechanisms
[5].
Genome-wide association studies (GWAS) query millions of
single nucleotide polymorphisms (SNPs) individually for their
association with either case-control status [6] or disease-specific
quantitative phenotypes, e.g., in the case of AD, regional brain
volumes [7] or brain amyloid burden [8]. Mass univariate analysis
of genetic data is still the predominant method, in virtue of its
ease-of-use and well-established theoretical framework, albeit
suffering from significant limitations including the requirement
for multiple testing, redundancies introduced by linkage disequi-
librium (LD) and the lack of analysis of epistatic effects (e.g.,
SNP-SNP interactions), which have to be explicitly modeled and
searched for exhaustively [9]. Moreover, more than one quanti-
tative phenotype can be derived from the available imaging data,
e.g., dozens or hundreds of regional brain volumes, or hundreds
of thousands of voxel-level metrics [10]. This potentially large
number of genotype-phenotypes features of interest generally
complicates the problem of reliably detecting statistical associ-
ations, and thus hampers the identification of disease-relevant
genetic markers by purely statistical means.
Limitations of classical mass-univariate statistical methods
have in recent years been overcome by employing multivariate
approaches to data analysis in the context of neuroscience studies
[11] and GWAS [12]. Likewise, in imaging-genetics meaningful
genotype-phenotype interactions [13] are captured by simulta-
neously modeling sets of genetic variants that are jointly associ-
ated with a given imaging phenotype [14,15,16,17]. Multivariate
GWAS have the potential to shed light on the complex genotype-
phenotype relationship, and may thus highlight novel links be-
tween brain physiology and molecular and biological functions.
However, although these methods have proven their ability to
Significance
In this study we employ a novel experimental imaging-
genetics approach for investigating the genetic underpinnings
of brain atrophy in Alzheimer’s disease. We successfully com-
bined state-of-art imaging-genetics methods and experimen-
tal gene expression data to uncover novel biology in brain at-
rophy. The novel experimental paradigm highlighted a signif-
icant role of TRIB3 (tribbles pseudokinase 3) in modulating the
typical pattern of Alzheimer’s brain pathology. This result cor-
roborates through rigorous data-driven statistical methods ev-
idence emerging from previous studies about the role of TRIB3
inmodulating knownmechanisms of neurodegeneration, such
as neuronal death, cellular homeostasis, and interaction with
established genes causing autosomal dominant Alzheimer’s
disease: APP and PSEN1. The developed integrated statistical-
experimental methodology could serve as a roadmap for in-
vestigations in other disorders.
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Fig. 1. Cross-validation scheme for the assessment
of the genetic loci of maximalgenotype-phenotype
correlation identified by the PLS model. The whole
procedure is repeated 1,000,000 times, and the result-
ing array is further analyzed. a) PLS is applied in a split-
half setting. For each of the two non-overlapping ran-
domly sampled groups, the PLS components of joint
phenotype and genotype variation are independently
estimated. b) Left. Each chromosome is partitioned in
bins of 10k base-pairs size, which are labeled 1 if they
contain a SNP associated to the largest PLS weights
(top 10% of absolute values), or 0 otherwise. To ob-
tain stable estimates of the loci of maximal weights,
the resulting binary arrays independently estimated in
the two groups aremerged (bin-wise AND operation).
The same procedure is applied on the mesh-based PLS
weights associated to the phenotype component. c)
Steps a) and b) are repeated across 1,000,000folds,
and the results are subsequently averaged to obtain
the confidence maps associated to genetic and phe-
notype components (figures 2 and 3).
Fig. 2. PLS genotype component: the circular plots show the probability
of a given genetic locus to be associated with the phenotype components
shown in Figure 3. Outer to inner circles represents components 1 to 3
respectively. Theplots show the probability of a given genetic bin of size 10kb
of being relevant in the PLS model, i.e., to contain a SNP that is ranked in the
top 10% of the absolute weights of the genotype component. The genes
with eQTLs close to the important loci (p>0.95) are listed in the innermost
circle depending on their genomic position. The red radial lines are located
in correspondence of known AD genes: ABCA7, APOE, APP, BIN1, CASS4,
CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB5, INPP5D,
MAPT, MEF2C, MS4, NME8, PICALM, PSEN1, PSEN2, PTK2B, SLC24A4, SORL1,
ZCWPW1. High-resolution circular plots for each component are provided in
Supplementary Figures S2, S3 and S4.
identify meaningful SNP combinations associated to brain imag-
ing features, the interpretation and validation of the statistical
findings remain very challenging tasks. These problems relate
directly to the understanding of the functional role of sets of
genetic variants, and to the difficulty of replicating the statistical
results in unseen cohorts.
We approach this technical bottleneck by leveraging multi-
variate approaches to explore high-dimensional datasets and to
generate hypotheses, which are subsequently tested in downstream
experiments. High-quality databases of matched genotype and
gene expression measurements such as the Genotype-Tissue-
Expression project1 (GTEx) [18] and BRAINEAC2 [19] facilitate
the quantification of effects of SNPs on gene expression in nu-
merous tissues, including various brain tissues. Typically, these
databases are used to detail the effect of a genetic variant at
the very end of an analysis pipeline and to garner evidence for
molecular mechanisms of the genetic locus. However, functional
information in ‘convenience’ databases can also be used at an
earlier stage in the analysis in order to prioritize a few candidate
hypotheses with a clear functional mechanism (e.g., expression
quantitative trait loci; eQTL) for the validation phase and thus
limit the multiple testing burden.
In this work we apply this novel investigative approach to
study the genetic functionalmechanisms underlying brain atrophy
in AD. The framework is comprised of two steps:
i) Statistical discovery. Candidate genetic variants are ini-
tially identified through data-driven multivariate statistical anal-
ysis of the matched imaging and genetics data (Figure 1). This is
achieved by modeling the joint covariation between 1.1 million
SNPs and the cortical and subcortical atrophy represented by
327,684 cortical and 27,120 sub-cortical thickness values of 639
individuals (either healthy older controls or patients with AD)
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
cohort;
ii) Functional prioritization. The candidate genetic variants
are subsequently screened for functional relevance by querying
high-dimensional gene expression databases such as GTEx.
The resulting small set of genetic loci, which are shown to
modify gene expression, is then validated in an independent sam-
ple of 553 individuals from ADNI diagnosed with mild cognitive
impairment (MCI), a proportion of whom progressed to AD.
Compared to previous approaches our work (i) analyses
the whole genome and whole brain in a hypothesis free fashion,
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Table 1. Socio-demographic, clinical, and genetic characteristic of the study cohort (mean, standard deviation). MCIc: MCI individual
subsequently converted to Alzheimer’s disease. MCIs: MCI individual not converted to Alzheimer’s disease during the observational
time. MMSE: mini mental state examination. ADAS: Alzheimer’s Disease Assessment Scale, 11 items. Apoe 4: Apolipoprotein E, allele 4.
Positivity to Aβ1-42 was defined with respect to the nominal cut-off of 192pg/ml.
Discovery Validation
Diagnosis at imaging Healthy AD MCI stable Progressing MCI
N 401 238 341 212
Age (years) 74.45 (5.5) 74.72 (7.9) 72.91 (7.6) 73.61 (7.51)
Education (years) 16.36 (2.66) 15.34 (2.9) 16.05 (2.87) 15.82 (2.82)
Sex (% females) 49 45 37 39
MMSE 29.1 (1.11) 23.2 (2) 27.91 (1.73) 26.87 (1.74)
ADAS11 5.98 (2.86) 19.85 (6.63) 9.29 (3.9) 13.31 (4.51)
Apoe 4 (% 0/1/2 alleles) 72/26/2 31/48/21 54/36/10 33/51/16
CSF Aβ1-42 (% positives, #subjects with baseline measure) 43% (282) 93% (166) 62% (244) 85% (135)
Table 2. Statistical comparison of the genes scores in training and
testing groups (Kruskal Wallis nonparametric test). The score for
TRIB3 leads to significant differences in the MCI testing group
after Bonferroni correction for multiple comparisons.
gene p-value training (AD
vs CT)
p-value testing (MCI conv vs
MCI stable)
TM2D1 0.0050 0.0528
IL10RA 0.1069 0.6198
TRIB3 0.0032 0.0034
ZBTB7A 0.0360 0.9135
LYSMD4 0.0000 0.2057
CRYL1 0.6213 0.1176
FAM135B 0.0000 0.5588
IP6K3 0.0000 0.4646
ITGA1 0.0993 0.7310
KIN 0.0014 0.2061
LAMC1 0.0019 0.0618
LINC00941 0.0000 0.6896
RBPMS2 0.0000 0.2149
RP11-
181K3.4
0.0017 0.0527
i.e., without preselecting SNPs or brain regions and (ii) uses a
functional prioritization step in order to select genetic loci for
validation in an independent cohort.
Starting from the initial 1.1 million SNPs, the multivariate
statistical analysis allowed the identification of a relatively small
number of genetic loci that are statistically associated with the
typical pattern of AD brain pathology. The subsequent functional
prioritization step ultimately identified a significant role ofTRIB3
(tribbles pseudokinase 3), a gene showing important connections
to known mechanisms of neurodegenerative diseases. Indeed,
although a role for TRIB3 in dementia has not been extensively
explored, there are several aspects of TRIB3 function that have
relevance to mechanisms related to neuronal death, cellular
homeostasis, and of interaction with established AD genes, such
as APP and PSEN1.
This study ultimately offers an illustration of the poten-
tial of effectively combining multivariate statistical modeling in
imaging-genetics with recent instruments available from compu-
tational biology, to lead to novel insights on the pathophysiology
of neurodegeneration.
Results
Model training and estimated components
Figures 2 and 3 show the relevant areas of the identified
joint genetic and phenotype variation, respectively, for the first
three PLS components through stability selection. The compo-
nents were very robust (100% reproducible) during the stability
selection procedure (Supplementary Methods). The fourth and
fifth components did not present any relevant locations (i.e., all
bins have p<0.95) after stability selection for both the genetic
modality and for the imaging modality.
Genetic components
The circular Manhattan plot (Circos v0.96 [20]) of Figure 2
shows the selection frequency for the PLS genotype components,
describing the importance of the genetic loci associated to cortical
thickness variation for component 1, 2 and 3. The plot shows the
probability of a given genetic bin of size 10kb of being relevant
in the PLS model, i.e., to contain a SNP that is ranked in the top
10%of the absolute weights of the genotype component. Spatially
contiguous loci generally show similar importance values, which
is caused by LD of these regions.
In the genetic components 1 through 3 a total of 118 bins
exceeded the selection frequency threshold (61, 50, 7 for com-
ponent 1,2 and 3, respectively). From these bins 402 (196, 181
and 25) influential SNPs were extracted and annotated with 98
genes through the Ensembl Variant Effect Predictor (VEP) for
GRCh37 (date accessed: 17th October 2016) [21]. The extended
APOE locus comprising APOE and TOMM40 was selected as the
highest scoring region in component 1. A total of 3,956 candi-
date SNP-gene pairs were considered for the GTEx-based eQTL
analysis in six tissues. However, a few genes did not show suffi-
cient expression levels in some tissues and these combinations
were excluded from the analysis, resulting in 1,598 unique SNP-
gene-tissue tests, of those 104 were significant at the Bonferroni
corrected p-value threshold (p=3.1e-5) (Dataset S1) linking to
14 genes (Dataset S2; Figure S5): CAPN9, CRYL1, FAM135B,
IL10RA, IP6K3, ITGA1, KIN, LAMC1, LINC00941, LYSMD4,
RBPMS2, RP11-181K3.4, TM2D1, and TRIB3. These genes are
listed in the innermost circle of Figure 2 depending on their
genomic position.
The independent validation of those 14 genes in the MCI
cohort confirmed TRIB3 (p=0.0034) (Table 2). Three additional
genes were (close to) nominal significance: TM2D1 (p=0.053),
LAMC1 (p=0.062), and RP11-181K3.4 (p=0.053) (Table 2).
Of note the top eQTL SNP for TRIB3 rs4813620 received
a p=0.06175 in stage I of a large AD GWAS [6]. However,
rs62191440, a SNP in strong LD with rs4813620 (D’=0.8469;
r2=0.6559) in the European population [22], received a p-value
of 0.00601 (Figure S6) and also constitutes an eQTL for TRIB3 in
various tissues inGTEx including brain tissues cortex and caudate
ganglia (Figure S7). Interestingly, when estimating the PLS com-
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Fig. 3. PLS Phenotype component: the figures in the top row show the topographical distribution of the PLS weights associated to the cortical and subcortical
brain areas. The absolute value of the weights is proportional to the importance of the underlying brain areas. The relevance of the brain areas is quantified
in the bottom row. The colours (red to white) indicate the probability of a brain area to be associated with the genotype component shown in Figure 2, and
quantify the probability of each cortical mesh points of being relevant in the PLS model, i.e., to be ranked among the top 10% of the absolute weights of the
phenotype component.
ponents on the sub-cohort of 279 training individuals with positive
CSF amyloid (Table 1) we achieved compatible validation results
in the independent MCI group. Within this setting, TRIB3 still
leads to marginally significant differences (p=0.0134) between
progressing and stable MCI (Table S1).
Morphometric components
Figure 3 shows the PLS phenotype components 1 through 3
along with the associated selection frequency describing the loci
of brain atrophy associated with genetic variation. The first com-
ponent is mainly associated to the thinning of the cortical mantle,
and is localized in temporal and posterior cingulate cortices. The
relevant areas at the subcortical level are primarily associated
with amygdalae and thalami. The second component is mostly
associated to the thinning of the subcortical areas (hippocampi
and amygdalae), and to the cortical thinning of the temporal areas
at the cortical level. The third component is similar to component
2, and describes a sub-cortical thickness pattern prevalent in
hippocampi, amygdalae, and thalami. At the cortical level, the
component is associated with the thinning of frontal cortices, and
to isolated spots located in the parahippocampal gyrus.
Discussion
In this work we modeled high-dimensional genome-wide SNP
data and brain-wide cortical thickness data via joint multivariate
statistical modeling and functional prioritization of genes through
bioinformatics annotation and a large eQTL database.
Our study ultimately identified a link betweenTRIB3 (tribbles
pseudokinase 3) and the stereotypical pattern of grey matter
loss in AD (cortical thinning in temporal and posterior cingulate
regions and subcortical atrophy). TRIB3 is a pseudokinase which
acts as a regulator of several signaling pathways. For example it
can interact directly with Akt and inhibit the pro-survival Akt
pathway [23]. TRIB3 expression is induced during neuronal cell
death [24] and recently increased levels of the TRIB3 protein
were found in dopaminergic neurons of the substantia nigra
pars compacta in patients with Parkinson’s disease [25]. TRIB3
expression is stress induced and increases in response to nerve
growth factor (NGF) deprivation; endoplasmatic reticulum (ER)
stress, and amino acid deprivation [24]. Although a role for
TRIB3 in dementia has not been extensively explored, there are
several aspects of TRIB3 function that have relevance to known
mechanisms of neurodegenerative disease. TRIB3 can interact
directly with P62 to modulate autophagic flux [26], an important
process in maintaining cellular homeostasis that is known to
be disrupted in neurodegeneration [27]. Knockdown of TRIB3
modulates PSEN1 stability [26] and a yeast two-hybrid screen
identified progranulin as a direct interaction partner of TRIB3
[28]. Intriguingly, it has recently been demonstrated that TRIB3
induces both apoptosis and autophagy in Aβ-induced neuronal
death, and silencing of TRIB3 was strongly neuroprotective [29].
These links warrant further investigation for a functional role of
TRIB3 in neuronal death in dementia.
These earlier findings align with our eQTL analysis where
carriers of the minor allele show increased TRIB3 expression
(Figure S5), which potentially lowers the threshold to TRIB3
mediated neuronal cell death. TRIB3 expression was modulated
by the identified SNP in various other tissues including the
caudate (Figure S7), a region affected in PD and Huntington’s
disease. A recent study of Trib3 expression in mice concluded that
“Trib3 has a pathophysiological role in diabetes” [30]; diabetes
itself is a known risk factor for dementia [31] perhaps through
sharedmetabolic processes with AD [32]. Interestingly, one of the
three SNPs (rs1555318) selected in the PLS model and attributed
to TRIB3 showed a strong association with type-2 diabetes in
stage 1 of a large GWAS (p=4.4e-4; Figure S8) [33]. Other
GWAS showed links between TRIB3 and information processing
speed (p=1.7e-7) [34] and AD (p=0.006; [6]). An earlier genetic
study on AD in Swedish men found an association in TRIB3 as
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
4 www.pnas.org --- --- Footline Author
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
Submission PDF
well (p=0.044; [35]), which was replicated in a Canadian cohort
(p<0.001 ; [36]). Lastly, TRIB3was reported to physically interact
with APP [37] and it shares numerous functional annotations for
biological processes regarding lipid metabolism with APOE.
The functional prioritization component of the analysis suc-
cessfully reduced the set of candidate genetic variants for the
independent validation, however, this prioritization has a short-
coming: it hypothesizes that identified SNPs alter the expres-
sion of a nearby gene. Although, this scheme led to the iden-
tification of TRIB3 in the cortical thickness phenotype, it did
miss a long-established AD risk gene: APOE. SNPs belonging
to APOE (rs429358 and rs7412) were selected as highest scoring
SNPs in component 1. However, none of them was detected as
an eQTL and thus APOE was excluded from the downstream
analysis. Other types of functional prioritizations based on exonic
function prediction may have retained APOE and other genes in
the pipeline. However, SNPs data typically features only a few
non-synonymous exonic variants and their high frequency (MAF
>5%) renders them unlikely to receive significant ‘damaging’
scores in these predictions. Thus, for this scenario the use of these
function predictions would be limited.
The list of genes we identified contains other interesting
candidates. For instance, IL10RA (interleukin 10 receptor sub-
unit alpha) is a receptor for interleukin 10 (IL10), a cytokine
that controls inflammatory response [38]. Carriers of the minor
allele show increased IL10RA expression (Figure S5) and Il10ra
expression is increased in affected brain regions with increasing
age and presence of AD pathology in transgenic mouse models
of AD (MOUSEAC; [39] Figure S9). Moreover, a link between
downregulation of IL10RA and TRIB3 in TRIB3-silenced HepG2
cells was reported in [26], along with increased abundance of Pre-
senilin 1, ApoE3, and Clusterin. Finally, blocking IL10 response
was recently suggested as a therapeutic mechanism in AD [40].
A gene that showed a statistical trend in the validation sample
was TM2D1 (TM2 domain containing 1), which is a beta-amyloid
binding protein and may be involved in beta-amyloid-induced
apoptosis [41]. Further, MEF2A (Myocyte Enhancer Factor 2A),
like APOE, was filtered out by the functional prioritization. How-
ever,MEF2A is a paralog ofMEF2C, which is an established AD
gene [6]. Noteworthy, bins covering MEF2C only barely missed
the selection threshold in component 2 for further analysis (max
p=0.926; Figure 2).
This study illustrates the potential of effectively combining
multivariate statistical modeling in imaging-genetics with recent
instruments available from computational biology, to lead to
novel insights on the disease pathophysiology. Thanks to the ever-
growing data-driven knowledge based on the vast quantities of in-
formation now available to the research community, the paradigm
proposed in this study may represent a promising avenue for
linking imaging-genetics findings to the current knowledge on
functional genetics mechanisms involved in neurodegeneration.
Materials and methods
This section describes the study data, the statistical setting and methodology
used in the present study. Further details and discussion about the method-
ological aspects can be found in the Supplementary Material (Methods
Section).
Study Participants
Data used in the preparation of this article were obtained from the
ADNI database (http://adni.loni.usc.edu). The ADNI was launched in 2003
as a public-private partnership, led by Principal Investigator Michael W.
Weiner, MD. For up-to-date information, see www.adni-info.org. This re-
search mainly involves further processing of previously collected personal
data. We have explicit authorization for the use of the ADNI dataset, and
we have signed the relevant papers guaranteeing that we abide to the ethics
standards.
We selected genotype and phenotype data available in the ADNI-1/GO/2
datasets for 1,192 subjects. Summary socio-demographic, clinical and genetic
information are available in Table 1. At time of study entry subjects were
diagnosed as healthy individuals (N=401), MCI (N=553) or AD (N=238). A total
of 212 (38.3%) MCI patients subsequently converted to AD over the course
of the study (6 years). All participants were non-Hispanic Caucasian. AD and
MCI groups show significant cognitive declinemeasured byMMSE andADAS-
COG as compared to the healthy individuals (p<1e-2, two sample t-test for
group-wise comparison). There was also a significant increase of individuals
with pathological levels of Aβ1-42 in the CSF (Aβ1-42 <192pg/ml) across the
clinical groups, with proportions ranging from 43% for healthy individuals
to 93% for AD patients (p<1e-2). Similarly, we observed a higher prevalence
of APOE4 carriers in AD and progressing MCI individuals when compared
to healthy and MCI stable groups. For this analysis, the 639 healthy and AD
subjects form the discovery set, while the MCI converters and non-converters
form the independent validation set.
Statistical Discovery
The joint relationship between the genetic and imaging modalities was
investigated through partial least squares (PLS) modeling [42,43,44]. Among
the several PLS versions proposed in the literature we focus on the symmetric
formulation of PLS computed through the singular value decomposition
(SVD) of the cross covariancematrix (Figure S1) [43,45,46].Within this setting,
the aim of PLS is to estimate the latent components that maximize the global
covariance between the two input modalities. Each input feature receives a
weight in the latent component that represents its relative importance for
describing the global joint multimodal relationship. Analyzing these weights
helps identifying SNPs that are linked to the patterns of cortical thinning in
the brain.
In this study we applied a robust approach for the stable estimation
and interpretation of PLS weights in genome-wide genotyping data, aimed
at promoting sparsity (i.e., selecting only few features for simplified inter-
pretation) and regularity (by aggregating SNPs within the same genetic
neighborhood). This is achieved through a stability selection procedure in
which the reproducibility and robustness of the PLS parameters is assessed
through a split-half cross-validation based scheme on 1,000,000 repetitions
of the models on randomly sampled subgroups (Figure 1 and supplementary
Methods). By considering a pre-defined partition of each chromosome into
contiguous loci of size 10kb, the procedure leads to the estimation of a
confidencemeasure taking values ranged between 0.0 and 1.0 indicating the
probability of each genetic loci to contain highly reproducible PLS weights,
and therefore serving as a measure of importance of the genomic location
(Figure 2). A similar procedure was employed to assess the importance of
the phenotype component (Figure 1). However, no regional binning was
employed (Figure 3). The procedure was applied to assess the parameter
reproducibility of the first five PLS modes; subsequent analyses were per-
formed only on components with relevant genetic and brain regions (i.e.,
reproducible PLS weights with selection frequency >95%). PLS components
and probability measures will be made available at the author’s website.
Gene identification
Weanalyzed the 10kb bins (genetic loci) with the selection frequency ex-
ceeding 0.95, i.e., bins selected in 95% or more of the 1,000,000 replications.
Within these bins we then identified the influential SNPs: a SNP was declared
influential if it was associated with the weights of greatest magnitude in the
PLS components estimated on the full data sample, i.e., SNPs with absolute
weights exceeding the 99th quantile of all weights in the component. These
weights are the ones contributing to the high selection frequency in the split-
half procedure, and are representative of the significant variation modeled
in the data.
In order to link SNPs to corresponding genes we used the computa-
tional VEP for GRCh37 with the GENCODE gene annotation. SNPs tagged
as ‘regulatory’ were manually investigated and annotated with the nearby
genes.
Functional prioritization
All SNPs successfully annotatedwith a genewere subjected to functional
prioritization through expression quantitative trait loci (eQTL) analysis based
on the GTEx data. The sample size in GTEx for relevant brain tissues in AD
was rather small (e.g., N=81 for hippocampus). Therefore, we added five
more tissues with large sample sizes that were more distantly relevant to
AD: nerve tibial (N=256) was added as a proxy for nervous tissue; whole
blood (N=338) and artery tibial (N=285) were included to cover blood-based
changes and effects on blood vessels [47] adipose subcutaneous (N=298) was
selected due to links between AD and obesity, type-2 diabetes andmetabolic
disease [48,49]. Finally, transformed fibroblasts (N=272) were included as a
general-purpose cell line. P-values were corrected for multiple testing using
the Bonferroni method.
Model validation in independent MCI subjects
The genes that were found to be under expression control by the
identified SNPs were validated for their capacity to predict clinical conversion
in MCI subjects. To this end, for each identified gene we applied the PLS
weights estimated on the discovery set on the validation set, with the genetic
component restricted to SNPs +/- 20kb of the gene borders. The identified
latent projections (i.e., a weighted sum of SNPs) results in one score per
subject per gene. For each gene the association of the projection score
with conversion status was assessed by statistically comparing the scores
distribution between healthy individuals and AD patients, and between MCI
converters and non-converters (Kruskal-Wallis non parametric test for two
sample comparison, Bonferroni correction for multiple comparisons).
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